Connect with us

Technology

Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation

Published

on

First of its Kind Scientific Collaboration Will Engage Top Research Institutes in Cambridge, UK with Flagship Pioneering

Focus on Scaling and Advancing Flagship’s Breakthrough Science and Technologies through the Cambridge Life Sciences Ecosystem

LONDON, Jan. 23, 2025 /PRNewswire/ — Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to collaborate to jointly advance breakthrough scientific research and technologies.

The collaboration will focus on research and innovation and will enable Flagship Pioneering’s ecosystem of more than 40 companies to partner with CUHP and MTI to access breakthrough science and technologies, clinical translation and trial support, and data assets and biosamples. It will also allow for career development opportunities with Flagship for Cambridge, UK scientists and students, including through the Flagship Fellowship.

Flagship will work with Cambridge University Health Partners and the Milner Therapeutics Institute to access exciting opportunities across other top organizations in the Cambridge, UK life sciences ecosystem, including the Wellcome Sanger Institute, the MRC Laboratory of Molecular Biology, the Babraham Institute, the University of Cambridge, the NIHR Cambridge Biomedical Research Centre, the NIHR Cambridge Clinical Research Facility, and the Cambridge University Hospitals NHS Trust. 

“Our collaboration with CUHP and MTI blends breakthrough research, clinical trial support, access to data assets, and accelerated talent development,” said Junaid Bajwa, M.D., Senior Partner and Head of the United Kingdom for Flagship Pioneering. “Cambridge is one of the centerpieces of the UK’s life sciences ecosystem, and Flagship has already witnessed firsthand how the US and UK Cambridge ecosystems can potentiate each other’s innovations, with the launch last year of our first co-located company, Quotient Therapeutics. We are pleased to announce this collaboration with CUHP and MTI roughly one year after opening our new London hub, and we expect to see further momentum in cooperation between the UK’s rich research and life science networks and Flagship and its companies.”

“This collaboration unites two of the world’s great drivers of life sciences innovation, the city of Cambridge, UK and Flagship Pioneering, in a bid to accelerate the cutting-edge medicines and global companies of tomorrow,” said Lord James O’Shaughnessy, Chair of Cambridge University Health Partners. “It is a fusion of scientific creativity, technological innovation, entrepreneurial flair and a can-do attitude, that will allow talent from our world-leading institutes the chance to pair their academic research with Flagship’s exciting and novel approach to inventing and building bioplatform companies. Ultimately, we all want to change the lives of patients and create successful businesses, and we’re thrilled to be Flagship’s UK academic partner.”

“Research collaborations like this can further propel the UK’s position as a hub for biotechnology innovation,” said Sir Tony Kouzarides, Director of the Milner Therapeutics Institute. “We are pleased to add Flagship’s unique approach to company creation and development to the thriving ecosystem that exists here in Cambridge, and look forward to seeing where the collaboration will lead.”

About Flagship Pioneering

Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

About Cambridge University Health Partners

Cambridge University Health Partners (CUHP) is one of eight Academic Health Science Centres in England, whose mission is to improve patient healthcare by bringing together the NHS, industry and academia. Along with leaders from across the Cambridge life sciences and healthcare ecosystem, CUHP devised and now implements the life science strategy for the Cambridge cluster. The partners are, Anglia Ruskin University (ARU), Cambridge and Peterborough NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Royal Papworth Hospital NHS Foundation Trust and the University of Cambridge.

About Milner Therapeutics Institute

The Milner Therapeutics Institute (MTI) is a purpose-built research institute at the University of Cambridge, with an overarching vision to convert pioneering science into therapies by driving academic-industry partnerships. The MTI demonstrates a world-leading model of start-up companies, academics and pharma working side by side.

The MTI has an in-house research programme that has  built a mass of expertise in computational research and functional genomics, and is the headquarters of the Milner Therapeutics Consortium, a partnership of nine Pharma companies and three academic Institutions that provides routes to engage with Cambridge academics and entrepreneurs. The MTI also provides space for start-ups through the Frame Shift Bio-incubator.

Media Contacts:

Flagship Pioneering
press@flagshippioneering.com

Cambridge University Health Partners 
comms@cuhp.org.uk

Milner Therapeutics Institute
Nikki Mann
ndo23@cam.ac.uk

 

Logo – https://mma.prnewswire.com/media/2156098/Flagship_Pioneering_Logo.jpg
Logo – https://mma.prnewswire.com/media/2604067/CUHP_logo_no_background_Logo.jpg
Logo – https://mma.prnewswire.com/media/2604044/Milner_Therapeutics_Institute_logo_master_RGB_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/flagship-pioneering-cambridge-university-health-partners-and-milner-therapeutics-institute-announce-collaboration-to-accelerate-biotech-research-and-innovation-302357819.html

Continue Reading

Technology

LEAP Group Relaunches HumanView, a Growth Intelligence System Built to Explain Why Customers Behave the Way They Do

Published

on

By

Reimagined from the ground up, HumanView pairs statistical modeling with expert analysts to turn millions of real-world customer signals into business decisions

LOUISVILLE, Ky., Oct. 23, 2026 /PRNewswire/ — LEAP Group today announced the relaunch of HumanView, its growth intelligence service. The new version has been rebuilt from the ground up and now has a dedicated home at leapgroupnetwork.com/humanview.

HumanView analyzes what customers say and do across social platforms, e-commerce sites, review platforms, search behavior and user-generated content, including signals from Reddit, TikTok, YouTube, Meta, Amazon and Walmart+ that general AI tools cannot always access. Because the data reflects unprompted, real-world behavior, it avoids the response bias built into surveys and focus groups.

The service works in three layers. HumanView captures signals at scale, decodes millions of records through validated statistical models such as regression, correlation and clustering, and then relies on experienced analysts to interpret the patterns. Clients receive clear, human-validated insights instead of another dashboard.

“Machines find the patterns. Humans find the point,” said Alan Gilleo, CEO at LEAP Group. “The first version of HumanView showed us how much customers reveal when nobody is asking them questions. This version is built to explain why they act the way they do, and to put those answers in front of everyone making decisions, from product to service to marketing.”

HumanView focuses on three areas:

Growth Intelligence: customer motivations and how people perceive a brand and its competitors

Market and Category Intelligence: product pain points, service friction, unmet needs and competitive gaps

Audience Intelligence: new segments, positioning opportunities and gaps in the market

Every model is designed and validated by data scientists and benchmarked before it informs a recommendation.

To learn more about HumanView, visit leapgroupnetwork.com/humanview.

About LEAP Group
LEAP Group is a boutique marketing agency holding company with offices in Louisville, Indianapolis, Cincinnati and Chicago. Guided by the belief that brands should “Market Less. Matter More.,” LEAP gives clients access to specialized experts across its entire network. Learn more at leapgroupnetwork.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-group-relaunches-humanview-a-growth-intelligence-system-built-to-explain-why-customers-behave-the-way-they-do-302918557.html

SOURCE LEAP Group

Continue Reading

Technology

STEPHEN A. SMITH ADDRESSES WHITE HOUSE DINNER ATTENDANCE, REAFFIRMS COMMITMENT TO HBCUs AND PROTECTING CORPORATE INVESTMENT IN BLACK EDUCATION

Published

on

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Stephen A. Smith, media mogul, New York Times bestselling author, and proud 1991 graduate of Winston-Salem State University, is addressing the public discussion surrounding his decision to attend a White House dinner with President Donald Trump, emphasizing his commitment to the long-term financial stability of Historically Black Colleges and Universities (HBCUs).

For Smith, the decision was rooted in a commitment to institutions that have educated generations of Black leaders, professionals, entrepreneurs, and public servants.

“I will always advocate for HBCUs and the students whose futures depend on them,” Smith said. “My reason for attending the White House dinner was to discuss the challenges these institutions face in securing long-term funding and to make the case that corporate America must continue to invest in them.”

Smith acknowledged federal support through the FUTURE Act while expressing concern that political tensions surrounding diversity, equity, and inclusion (DEI) could discourage private companies from supporting HBCUs. He maintains that these institutions deserve sustained corporate partnerships, philanthropic contributions, and public investment.

“If we truly believe in free-market capitalism, businesses should be able to support educational institutions and charitable causes without fear of criticism or repercussions,” Smith said. “HBCUs have made extraordinary contributions to this country. They deserve sustained public and private investment.”

Ashley Christopher, Esq., Founder and CEO of the HBCU Week Foundation, recognized Smith’s advocacy and decision to engage with the administration.

“Stephen A. Smith has been a powerful advocate for HBCUs, using his platform and influence to shine a national spotlight on our institutions,” expressed Christopher, “His continued support of HBCU Week helps advance our mission of connecting students with life-changing educational opportunities, and we are proud to have him as our ambassador.”

Since Smith became an HBCU Week Ambassador in 2019, the initiative has facilitated more than 15,000 on-the-spot college acceptances and raised and awarded more than $150 million in scholarships, according to the HBCU Week Foundation.

As public discussion continues, Smith is emphasizing the importance of ensuring HBCUs have the resources and partnerships needed to educate future generations and expand opportunities for students.

CLICK HERE to watch Smith’s full response to his White House visit.

MEDIA CONTACT:

media@mrsasinc.com

View original content:https://www.prnewswire.com/news-releases/stephen-a-smith-addresses-white-house-dinner-attendance-reaffirms-commitment-to-hbcus-and-protecting-corporate-investment-in-black-education-302918547.html

SOURCE Straight Shooter Media

Continue Reading

Technology

Advantex Announces Completion of Financing and Extension of Maturity Date of Previously Issued Debentures

Published

on

By

TORONTO, Oct. 23, 2026 /CNW/ — Advantex Marketing International Inc. (CSE: ADX) (“Advantex”), a leader in the merchant cash advance and loyalty marketing products for merchants, today announced the completion of a $250,000 secured debt financing. Advantex issued a $250,000 non-convertible debenture which bears an interest rate at 12% per annum and matures December 15, 2027. The proceeds raised from this issuance of the Debenture will be used for working capital purposes.

Advantex has also extended the maturity of its existing $700,000 in 12% secured debentures from October 10, 2026 to December 15, 2027.

About Advantex Marketing International Inc.

Advantex provides working capital to merchants. Advantex also provides specialized marketing programs that enable members of Aeroplan to earn Aeroplan points at participating merchants.

Advantex shares trade on the Canadian Securities Exchange under the symbol ADX. For more information go to Advantex’s profile on www.sedar.com

Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable securities laws relating to the future business and operations of Advantex. Actual results and developments may differ materially from those contemplated by these statements. The business and operations of Advantex described herein is dependent on a number of factors and is subject to a number of risks and uncertainties. Factors that could cause actual results to differ material include, but are not limited to, changes in Advantex’s economic and competitive conditions including but not limited to the industry sectors in which Advantex operates.

The statements in this news release are made of the date of this release. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and Advantex undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law.

SOURCE Advantex Marketing International Inc.

Continue Reading

Trending